Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Name: Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein
Brand: Puweituo Bio
SKU: KRASG12V-HB001

Catalog numberKRASG12V-HB001

HumanE. coliMolecule · MHCMolecular weight · 35.36 kDa

Product introduction

Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVGAVGVGK).

Product details

Molecular aliases: MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein length: Gly25-Thr305
Expression system: E. coli
Molecular weight: The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Purity: > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin: Less than 1 EU per μg by the LAL method.
Formulation: Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
Storage: Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data display

Bis-Tris PAGE Data — Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC Data — The purity of Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.

ELISA Data — Immobilized Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 6.2ng/ml determined by ELISA (QC Test).

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

References

1.(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

加载中…

Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Catalog numberKRASG12V-HB001

HumanE. coliMolecule · MHCMolecular weight · 35.36 kDa

Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

ELISA

ELISA Data

Background

References

Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

ELISA

ELISA Data

Background

References